NYU Langone Issues $580,000 Purchase Order for Inspira's FDA-Cleared ART100 Following Multi-Patient Hospital Evaluation
NYU Langone Hospital has placed a $580,000 commercial purchase order for Inspira Technologies' FDA-cleared ART100 extracorporeal blood circulation systems following a successful multi-patient clinical evaluation. The order represents a significant commercial milestone for the Israeli medical technology company's blood oxygenation platform, with systems scheduled for immediate delivery through Inspira's U.S. distributor. The ART100 system provides extracorporeal blood circulation capabilities, offering an alternative approach to traditional mechanical ventilation for patients with severe respiratory conditions. The purchase follows clinical testing at the New York medical center that demonstrated the technology's effectiveness in real-world hospital settings. This commercial deployment comes as Inspira continues pursuing strategic opportunities around its ART100 platform and broader medical device portfolio, potentially signaling growing adoption of the company's respiratory support technology in major U.S. healthcare systems.
Why It Matters
This represents validation of an alternative respiratory support technology that could reduce dependence on traditional mechanical ventilation. The fact that a prestigious medical center like NYU Langone moved from clinical evaluation to commercial purchase suggests the technology demonstrated clear clinical benefits, potentially opening pathways for broader adoption across healthcare systems facing critical care capacity challenges.
This summary is generated using AI analysis of the original press release. Always refer to the original source for complete details.